Among the challenges to faster progress in gene-editing therapeutics is the requirement that corrections of inherited genetic mutations occur in tissue stem cells. Last week on May 4-5 at the Precision Medicine Symposium-2016 in Burlington, Massachusetts, Boston’s stem cell medicine technology company, Asymmetrex, presented two of the company’s technologies that can address this challenge by counting tissue stem cells for the first time and expanding their numbers for gene-editing.
(PRWeb May 12, 2016)
Read the full story at http://www.prweb.com/releases/2016/05/prweb13410352.htm
For more information, please visit
http://www.prweb.com/releases/2016/05/prweb13410352.htm